Skip To Main Content
Mengxia Li on Muck Rack

Mengxia Li

As seen in: Nature, Journal of Retailing and Consumer Services, MDPI, JAMA: Journal of the American Medical Association, Royal Society of Chemistry, BioRxiv, Canadian Journal of Infectious Diseases & Medical Microbiology, JoVE- Journal of Visualized Experiments, The Journal of Biological Chemistry, Future Medicine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mengxia

Contact Mengxia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer : The HARMONi-A Randomized Clinical Trial

|
By HARMONi-A Study Investigators, Wenfeng Fang, Yuanyuan Zhao, Yongzhong Luo, Runxiang Yang, Yan Huang, Zhiyong He, Hui Zhao, Mingjun Li, Kai Li, Qibin Song, Xiaobo Du, Yulan Sun, Wei Li, Longhua Sun, Zhiyu Wang, Kunning Yang, Yun Fan, Baogang Liu, Hongyun Zhao, Ying Hu, Li Jia, Shen Xu, Tienan Yi, Dongqing Lv, Haitao Lan, Mengxia Li, Wenhua Liang, Yongsheng Wang, Hui Yang, Yuming Jia, Yuan Chen, Meiqi Shi, Chunling Liu, Ming Zhou, Jianya Zhou, Xianling Liu, Ningning Zhou, Ming He, Xiaorong Dong, Hualin Chen, Yongxing Chen, Haichuan Su, Xiaoling Li, Zhihong Zhang, Ying Liu, Likun Chen, Xue Hou, Yu Zhang, Jun Guo, Ruiqiang Ma, Hong Lu, Di Wu, Weineng Feng, Jianan Huang, Yan Wang, Xia Song, Jiewen Peng, Laiyu Liu, Yubiao Guo, Mengying Xia, Dongmei Lu, Mingxiu Hu, Zhongmin Wang, Baiyong Li, Michelle Xia, Li Zhang, Junguo Lu
| JAMA: Journal of the American Medical Association Verified
Key Points Question Does adding ivonescimab to chemotherapy improve overall survival in patients with epidermal growth factor receptor (EGFR) gene variant non–small cell lung cancer after disease progression with EGFR tyrosine kinase inhibitor (TKI) therapy? Findings In this phase 3, randomized, double-blind trial, ivonescimab plus chemotherapy significantly improved overall survival (median, 16.8 vs 14.1 months) and the 30-month survival rate (29.1% vs 18.4%) compared with chemotherapy alone.
Open in Who Shared Issue with article?

Tumor genome and microenvironment alteration by trastuzumab deruxtecan as neoadjuvant therapy for HER2-mutant NSCLC

|
By Xianfeng Lu, Shuai Yue, Ruyi Hang, Xiaoyan Dai, Wei Guo, Zhou Huang, Yanli Xiong, Mengxia Li, Jiangyang Li, Xunjie Kuang
| Nature Verified
Abstract Non-small cell lung cancer (NSCLC) patients carrying HER2 exon 20 insertion (HER2 20ins) are respond poorly to conventional therapies and pan HER inhibitors. Trastuzumab Deruxtecan (T-DXd) has been approved in second line treatment in advanced NSCLC, but its efficacy in operable patients remains unclear.
Open in Who Shared Issue with article?

ACTB hypermethylation in blood is a potential biomarker as predictor to the risk of coronary heart disease

|
By Jialie Jin, Fei Wang, Mengxia Li, Yao Fan, Yu Chi Liu, Haifeng Xu, Changying Chen, Lai Wei, Fangyuan Liu, Chong Shen, Rongxi Yang
| Nature Verified
Abstract Potential biomarkers that can assess the risk of coronary heart disease (CHD) and facilitate its preclinical detection are urgently needed. We aimed to explore the association between blood-based ACTB methylation and future CHD risk in a nested case-control study in the Chinese population. The methylation level of ACTB was quantitatively determined by mass spectrometry in 171 subclinical CHD cases and 356 controls.
Open in Who Shared Issue with article?
See all 20 licensed articles (22 Total)